Mallucci, Giulia http://orcid.org/0000-0002-0031-9594
Annovazzi, P.
Miante, S.
Torri-Clerici, V.
Matta, M.
La Gioia, S.
Cavarretta, R.
Mantero, V.
Costantini, G.
D’Ambrosio, V.
Zaffaroni, M.
Ghezzi, A.
Perini, P.
Rossi, S.
Bertolotto, A.
Rottoli, M. R.
Rovaris, M.
Balgera, R.
Cavalla, P.
Montomoli, C.
Bergamaschi, R.
Article History
Received: 7 February 2018
Revised: 22 May 2018
Accepted: 23 May 2018
First Online: 14 June 2018
Compliance with ethical standards
:
: G. Mallucci received support to travel to scientific meetings from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva; received speaker honoraria from Biogen Idec and served on the scientific advisory board for Genzyme and Merck Serono. P. Annovazzi received honoraria for lecturing and participation in advisory boards, and/or travel expenses for attending congresses and meetings from Merck, Biogen, Teva, Sanofi-Genzyme, Almirall, Mylan, Roche and Novartis. S.Miante received a travel grant form Biogen Idec, Novartis, Sanofi-Aventis and Teva. V. Torri-Clerici acted as an Advisory Board member of Merck Serono, Novartis and Genzyme, and received funding for travelling and honoraria for speaking or writing or consultancy from Biogen Idec, Merck, Teva, Novartis, Genzyme, and Almirall. She received support for research project by Almirall and is involved as principal investigator in clinical trials for Novartis and Merck. M. Matta has nothing to disclose. S. La Gioia received grants from Biogen for travel and congress participation. R. Cavarretta has nothing to disclose. V. Mantero has nothing to disclose. G. Costantini has nothing to disclose. V. D’Ambrosio has nothing to disclose. M. Zaffaroni received honoraria for consultancy and participation in advisory boards or travel grants from Genzyme, Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, and Novartis. A. Ghezzi has served on scientific advisory boards for Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd; has received speaker honoraria from Merck Serono, Biogen Idec, Bayer Schering Pharma Novartis, and Serono Symposia International; served as a consultant for Novartis; and receives research support from Sanofi-Aventis, Biogen Idec and Merck Serono. P. Perini has received funding for travel and speaker honoraria from Merck Serono, Biogen Idec, Sanofi-Aventis, and Bayer Schering Pharma and has been a consultant for Merck Serono, Biogen Idec and Teva. S. Rossi acted as an Advisory Board member of Biogen Idec, Bayer Schering, Merck Serono, Teva, Novartis and Genzyme, and received funding for travelling and honoraria for speaking or writing from Biogen Idec, Merck Serono, Teva, Novartis, Bayer Schering, Genzyme, Almirall. She received support for research project by Teva, Merck Serono and Bayer Schering and is involved as principal investigator in clinical trials for Teva and Roche. A. Bertolotto served on the scientific advisory boards of Almirall, Bayer, BiogenIdec, and Genzyme; received speaker honoraria from BiogenIdec, Genzyme, Novartis, and Teva; his institution has received grant support from Bayer, BiogenIdec, Merck, Novartis, Teva, the Italian Multiple Sclerosis Society, Fondazione Ricerca Biomedica ONLUS, and San Luigi ONLUS; received speaker honoraria from BiogenIdec, Genzyme, Novartis, Sanofi-Aventis, and Teva; is on the editorial board of Multiple Sclerosis International, Progress in Neuroscience, Dataset Papers in Neuroscience, Journal of Multiple Sclerosis, Neurology and Therapy, and Multiple Sclerosis and Demyelinating Disorders; and received research support from Regione Piemonte, Italian Multiple Sclerosis Society, Associazione Ricerca Biomedica ONLUS, and San Luigi ONLUS. MR Rottoli has nothing to disclose. M. Rovaris received compensation from Biogen Italy, Teva Pharmaceuticals, Novartis, and Genzyme for speaking and consultant fees. Dr. Rovaris received financial support for research activities from Teva Pharmaceuticals and Merck Serono. R. Balgera has nothing to disclose. P. Cavalla acted as an Advisory Board member of Merck Serono and Genzyme, and received funding for travelling and honoraria for speaking or consultancy from Biogen Idec, Merck Serono, Teva, Novartis, Genzyme and Almirall. She is involved as principal investigator in clinical trials for Novartis, Biogen and Genzyme. C. Montomoli received teaching grants from Biogen Idec and Merck Serono. R. Bergamaschi received research grants from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva received lecture honoraria from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Teva; and received support to travel to scientific meetings from Almirall, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Teva.